Introduction
Talaparib 1 mg (Talazoparib) Capsule is a targeted oral anticancer therapy used in specific genetic subtypes of breast and prostate cancer. As a potent PARP inhibitor, it is designed to block cancer cell repair mechanisms, making it especially effective in patients with BRCA mutations or HRR gene mutations. Manufactured by Everest Pharmaceuticals Ltd and globally supplied by Onco Solution, Talaparib is an essential addition to precision oncology.
Key Benefits
- Effective in BRCA-mutated HER2-negative metastatic breast cancer
- Used in HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC)
- Targeted mechanism minimizes damage to healthy cells
- Administered orally for convenience
Indications
1. BRCA-mutated (gBRCAm) HER2-negative Advanced or Metastatic Breast Cancer
Talaparib is indicated as a monotherapy for adult patients with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.
2. HRR Gene-mutated mCRPC
In combination with Enzalutamide, Talaparib is used in adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
Mechanism of Action (Pharmacology)
Talazoparib inhibits PARP1 and PARP2 enzymes, which are involved in DNA repair. By inhibiting these enzymes, Talaparib increases DNA damage in cancer cells, resulting in cell death. This targeted approach is especially effective in tumors with BRCA1, BRCA2, and other homologous recombination repair (HRR) gene mutations.
Dosage & Administration
For BRCA-mutated Breast Cancer:
- Dosage: 1 mg orally once daily
- Duration: Continue until disease progression or unacceptable toxicity
- Instructions: Take with or without food; do not open or crush the capsule
For HRR Gene-mutated mCRPC:
- Dosage: 0.5 mg orally once daily in combination with Enzalutamide
- Instructions: Same as above
Always follow a registered physician’s guidance before starting or modifying dosage.
Drug Interactions
P-gp Inhibitors (e.g., Itraconazole, Verapamil):
- Can increase Talaparib levels, increasing the risk of adverse effects
- Dose adjustments may be needed
BCRP Inhibitors:
- May increase Talaparib exposure
- Monitor for increased toxicity and modify dosage as needed
Contraindications
- Pregnancy: Can cause embryo-fetal harm
- Severe myelosuppression or unresolved hematological toxicities
Side Effects
Common (>20%):
- Anemia, neutropenia, thrombocytopenia
- Nausea, vomiting, diarrhea
- Fatigue, decreased appetite
- Elevated liver enzymes (AST, ALT)
- Headache, alopecia
Use in Special Populations
- Pregnancy: Contraindicated; use effective contraception
- Lactation: Not recommended; unknown if excreted in breast milk
- Geriatric: No overall differences in safety observed
- Pediatric: Safety not established
- Renal Impairment: Dosage reduction required in moderate to severe impairment
- Hepatic Impairment: No dosage adjustment needed
Precautions & Warnings
Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML):
- Discontinue if diagnosed
Myelosuppression:
- Monitor CBC regularly
- Discontinue if unresolved after 28 days
Embryo-Fetal Toxicity:
- Warn women of childbearing potential
Infertility:
- Potential impact on male fertility
Storage
- Store below 30°C
- Keep in a dry place, protected from light
- Keep out of reach of children
Supplier & Manufacturer Information
Manufacturer: Everest Pharmaceuticals Ltd
Supplier: Onco Solution – www.oncosolution.com
Conclusion
Talaparib 1 mg (Talazoparib) Capsule is a critical treatment option for patients with BRCA-mutated breast cancer and HRR gene-mutated prostate cancer. With a targeted mechanism, proven clinical benefits, and a manageable safety profile, it is a valuable oncology solution. Onco Solution is proud to supply this essential medicine worldwide in partnership with Everest Pharmaceuticals Ltd.
